Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan
- 1 January 2005
- journal article
- clinical trial
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 94 (10) , 808-813
- https://doi.org/10.1160/th05-03-0197
Abstract
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren ZeitschriftenartikelnKeywords
Funding Information
- Bayer Fellowship Grant (NIH HL-072676-01)
This publication has 19 references indexed in Scilit:
- Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient miceBlood, 2004
- The Effects of Argatroban on Thrombin Generation and Hemostatic Activation In VitroAnesthesia & Analgesia, 2004
- High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary InterventionCirculation, 2004
- Complete antithrombin deficiency in mice results in embryonic lethalityJournal of Clinical Investigation, 2000
- Altered Dermatan Sulfate Structure and Reduced Heparin Cofactor II-stimulating Activity of Biglycan and Decorin from Human Atherosclerotic PlaquePublished by Elsevier ,2000
- Antithrombin activity during the period of percutaneous coronary revascularization: Relation to heparin use, thrombotic complications and restenosisJournal of the American College of Cardiology, 1999
- Dermatan sulphate in patients with heparin-induced thrombocytopeniaBritish Journal of Haematology, 1999
- Heparin cofactor II in diabetic patientsBlood Coagulation & Fibrinolysis, 1994
- Significance of High Levels of Heparin Cofactor II in the Plasma and Urine of Adult Patients with Nephrotic SyndromeNephron, 1992
- Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysisClinical and Laboratory Haematology, 1989